rs193922688
Variant names:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_006261.5(PROP1):c.301_302delAG(p.Leu102CysfsTer8) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000191 in 1,613,694 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.00013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.00020 ( 0 hom. )
Consequence
PROP1
NM_006261.5 frameshift
NM_006261.5 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 3.32
Genes affected
PROP1 (HGNC:9455): (PROP paired-like homeobox 1) This gene encodes a paired-like homeodomain transcription factor in the developing pituitary gland. Expression occurs prior to and is required for expression of pou domain transcription factor 1, which is responsible for pituitary development and hormone expression. Mutations in this gene have been associated with combined pituitary hormone deficiency-2 as well as deficiencies in luteinizing hormone, follicle-stimulating hormone, growth hormone, prolactin, and thyroid-stimulating hormone. [provided by RefSeq, Sep 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.558 CDS is truncated, and there are 0 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 5-177994145-ACT-A is Pathogenic according to our data. Variant chr5-177994145-ACT-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 8098.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PROP1 | NM_006261.5 | c.301_302delAG | p.Leu102CysfsTer8 | frameshift_variant | Exon 2 of 3 | ENST00000308304.2 | NP_006252.4 |
Ensembl
Frequencies
GnomAD3 genomes 0.000132 AC: 20AN: 151820Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
20
AN:
151820
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000163 AC: 41AN: 251252Hom.: 0 AF XY: 0.000118 AC XY: 16AN XY: 135850
GnomAD3 exomes
AF:
AC:
41
AN:
251252
Hom.:
AF XY:
AC XY:
16
AN XY:
135850
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000198 AC: 289AN: 1461874Hom.: 0 AF XY: 0.000208 AC XY: 151AN XY: 727234
GnomAD4 exome
AF:
AC:
289
AN:
1461874
Hom.:
AF XY:
AC XY:
151
AN XY:
727234
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome 0.000132 AC: 20AN: 151820Hom.: 0 Cov.: 31 AF XY: 0.0000944 AC XY: 7AN XY: 74154
GnomAD4 genome
AF:
AC:
20
AN:
151820
Hom.:
Cov.:
31
AF XY:
AC XY:
7
AN XY:
74154
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:19Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Pituitary hormone deficiency, combined, 2 Pathogenic:11Other:2
| Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Oct 08, 2020 | This variant was identified as compound heterozygous with NM_006261.4:c.358C>T. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 20, 2022 | - - |
| not provided, no classification provided | literature only | GeneReviews | - | Common variant in Europe & Latin America [Dusatkova et al 2016]; founder variant in Lithuania [Navardauskaite et al 2014] & Hutterite population [Wu et al 1998]; Impaired gonadotropic function occurs in all individuals with the most common PROP1 variant, c.301_302delAG [Madeira et al 2017]. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 27, 2024 | - - |
| not provided, no classification provided | phenotyping only | GenomeConnect - Brain Gene Registry | - | Variant interpreted as Likely pathogenic and reported on 01-14-2020 by Lab PreventionGenetics. Assertions are reported exactly as they appear on the patient provided laboratory report. GenomeConnect does not attempt to reinterpret the variant. The IDDRC-CTSA National Brain Gene Registry (BGR) is a study funded by the U.S. National Center for Advancing Translational Sciences (NCATS) and includes 13 Intellectual and Developmental Disability Research Center (IDDRC) institutions. The study is led by Principal Investigator Dr. Philip Payne from Washington University. The BGR is a data commons of gene variants paired with subject clinical information. This database helps scientists learn more about genetic changes and their impact on the brain and behavior. Participation in the Brain Gene Registry requires participation in GenomeConnect. More information about the Brain Gene Registry can be found on the study website - https://braingeneregistry.wustl.edu/. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 06, 2024 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Pittsburgh Clinical Genomics Laboratory, University of Pittsburgh Medical Center | May 04, 2022 | This sequence variant is a two nucleotide deletion (delAG) at position c.301_302 of the coding sequence in exon 2 of 3 in the PROP1 gene. The c.301_302del allele has multiple desigtions and may be referred to as A301G302, 296delAG, or GA296 in the literature. This deletion results a premature termition sigl 8 codons downstream of the frameshift introduced at codon 102. While this variant is not expected to undergo nonsense mediated decay, a premature termition at this position would elimite the PROP1 protein's D binding and transcriptiol activation domains which are crucial to this protein's role in regulating the growth of the pituitary gland (PMID: 15591534). This is a previously reported variant (ClinVar) and is one of the most common variants associated with combined pituitary hormone deficiency (PMID: 31090814, 27828722). This variant has been observed in both the homozygous and compound heterozygous states in numerous individuals with combined pituitary hormone deficiency (PMID: 9745452, 11081182, 10084575, 10323394, 9462743) and has been observed to co-segregate with combined pituitary hormone deficiency in multiple individuals across a six-generation pedigree (PMID: 10634415). This variant is observed in control population datasets (gnomAD database, 51 of 282,522 alleles, 0.02%). A functiol alysis of the protein generated by this variant has confirmed that D binding and transactivation is significantly reduced by the variant relative to the wildtype protein (PMID: 9462743). Given this information, we consider this a pathogenic variant. ACMG Criteria: PM3, PP1, PS3, PVS1 - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2004 | - - |
| Pathogenic, criteria provided, single submitter | curation | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Feb 01, 2024 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
| Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics Laboratory, University Hospital Schleswig-Holstein | Jun 02, 2022 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 12, 2019 | NM_006261.4(PROP1):c.301_302delAG(aka L102Cfs*8) is classified as pathogenic in the context of combined pituitary hormone deficiency, PROP1 related. Sources cited for classification include the following: PMID 9462743 and 15126542. Classification of NM_006261.4(PROP1):c.301_302delAG(aka L102Cfs*8) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Sep 13, 2017 | The PROP1 c.301_302delAG (p.Leu102CysfsTer8) variant results in a frameshift and is predicted to result in premature termination of the protein and loss of the DNA-binding homeodomain and C-terminal transactivation domain (Wu et al. 1998). Across a selection of the available literature, the p.Leu102CysfsTer8 variant has been reported in a total of 280 individuals with combined pituitary hormone deficiency, including 213 homozygotes, 64 compound heterozygotes, and three heterozygotes in whom a second variant was not been identified (Wu et al. 1998; Cogan et al. 1998; Fofanova et al. 1998; Deladoey et al. 1999; Mendonca et al. 1999; Pernasetti et al. 2000; Riepe et al. 2001; Lee et al. 2004; Avbelj Stefanija et al. 2015; Lazea et al. 2015; Dusatkova et al. 2016). The p.Leu102CysfsTer8 variant was shown to segregate with disease in a four-generation family (Pernasetti et al. 2000). The variant was absent from 193 controls but is reported at a frequency of 0.00109 in the European American population of the Exome Sequencing Project. Based on the collective evidence and the potential impact of frameshift variants, the p.Leu102CysfsTer8 variant is classified as pathogenic for combined pituitary hormone deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
not provided Pathogenic:5
| Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Jul 04, 2023 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 27, 2024 | This sequence change creates a premature translational stop signal (p.Leu102Cysfs*8) in the PROP1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 125 amino acid(s) of the PROP1 protein. This variant is present in population databases (rs193922688, gnomAD 0.03%). This premature translational stop signal has been observed in individuals with combined pituitary hormone deficiency in many families and it has been observed in combination with another PROP1 variant in unrelated individuals with this condition (PMID: 9462743, 11081182, 16735499, 17162714, 26111865, 28734020). It has also been observed to segregate with disease in related individuals. This variant is also known as A301G302 deletion and delGA296 (S109X). ClinVar contains an entry for this variant (Variation ID: 8098). Algorithms developed to predict the effect of variants on gene product structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects PROP1 function (PMID: 9462743). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 11, 2024 | Frameshift variant predicted to result in abnormal protein length as the last 125 amino acids are replaced with 7 different amino acids, and other similar variants have been reported in HGMD; Published functional studies demonstrate a damaging effect on DNA binding and transactivation function (PMID: 9462743); This variant is associated with the following publications: (PMID: 28734020, 12414875, 16984240, 17526936, 15472175, 10084575, 25581745, 30959475, 31948187, 31090814, 31093944, 32415500, 33098107, 11081182, 26111865, 10323394, 15126542, 10634415, 26059845, 17162714, 16735499, 16703408, 18157385, 11022176, 9462743, 11549674, 30266296, 34426522, 31589614, 32612575, 9745452) - |
| Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 28, 2017 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 11, 2012 | - - |
46,XY partial gonadal dysgenesis Pathogenic:1
| Pathogenic, criteria provided, single submitter | research | Laan Lab, Human Genetics Research Group, University of Tartu | Aug 01, 2020 | - - |
Combined pituitary hormone deficiencies, genetic form Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing;curation | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 18, 2011 | - - |
PROP1-related disorder Pathogenic:1
| Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 05, 2024 | The PROP1 c.301_302delAG variant is predicted to result in a frameshift and premature protein termination (p.Leu102Cysfs*8). This variant in the homozygous or compound heterozygous state has been reported in individuals with combined pituitary hormone deficiency in many families (see example: Wu et al. 1998. PubMed ID: 9462743; Avbelj Stefanija et al. 2015. PubMed ID: 26111865; Blum et al. 2018. PubMed ID: 30266296). This variant is reported in 0.033% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in PROP1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DL_spliceai
Position offset: -39
Find out detailed SpliceAI scores and Pangolin per-transcript scores at